CO6410302A2 - Métodos para tratar el cancer - Google Patents

Métodos para tratar el cancer

Info

Publication number
CO6410302A2
CO6410302A2 CO11095925A CO11095925A CO6410302A2 CO 6410302 A2 CO6410302 A2 CO 6410302A2 CO 11095925 A CO11095925 A CO 11095925A CO 11095925 A CO11095925 A CO 11095925A CO 6410302 A2 CO6410302 A2 CO 6410302A2
Authority
CO
Colombia
Prior art keywords
methods
administration
treat cancer
formulated
oral
Prior art date
Application number
CO11095925A
Other languages
English (en)
Inventor
Edmon J Lavoie
Beverly Teicher
Steven Schmid
Original Assignee
Univ Rutgers
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410302(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Rutgers, Genzyme Corp filed Critical Univ Rutgers
Publication of CO6410302A2 publication Critical patent/CO6410302A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El invento proporciona métodos y composiciones farmacéuticas para tratar ciertos cánceres con compuestos de la fórmula I:donde A, B, W, Y, Z, y R1 tienen cualquiera de los significados definidos en la especificación y sus sales y profármacos farmacéuticamente aceptables, que pueden ser formulados para su administración oral, bucal, intranasal, parenteral (por ejemplo, intravenoso, intramuscular o subcutáneo), rectal, en una forma adecuada para la administración mediante inhalación o insuflación, o los compuestos activos pueden ser formulados para administración tópica.
CO11095925A 2009-01-30 2011-07-29 Métodos para tratar el cancer CO6410302A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14888109P 2009-01-30 2009-01-30
US24087309P 2009-09-09 2009-09-09

Publications (1)

Publication Number Publication Date
CO6410302A2 true CO6410302A2 (es) 2012-03-30

Family

ID=42077313

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11095925A CO6410302A2 (es) 2009-01-30 2011-07-29 Métodos para tratar el cancer

Country Status (19)

Country Link
US (1) US20120004235A1 (es)
EP (1) EP2391364A1 (es)
JP (1) JP2012516849A (es)
KR (1) KR20110122141A (es)
CN (1) CN102395368A (es)
AR (1) AR075346A1 (es)
AU (1) AU2010208042A1 (es)
BR (1) BRPI1008155A2 (es)
CA (1) CA2749204A1 (es)
CL (1) CL2011001850A1 (es)
CO (1) CO6410302A2 (es)
EA (1) EA201101140A1 (es)
IL (1) IL213919A0 (es)
MX (1) MX2011008069A (es)
NZ (1) NZ593849A (es)
PE (1) PE20120112A1 (es)
SG (1) SG173454A1 (es)
TW (1) TW201038578A (es)
WO (1) WO2010088544A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2403856T3 (da) * 2009-03-06 2013-04-08 Univ Rutgers Methylendioxybenzo[i]phenanthridinderivater anvendt til behandling af cancer
JP2019515025A (ja) 2016-04-04 2019-06-06 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー トポイソメラーゼ毒
CN108690034A (zh) * 2018-01-12 2018-10-23 兰州大学 一种氟化苯并萘啶酮类衍生物、制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2001032631A2 (en) 1999-10-29 2001-05-10 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
AU2002352708A1 (en) * 2001-11-14 2003-05-26 Edmond J. Lavoie Cytotoxic agents
DK1465625T3 (da) * 2001-11-14 2010-05-31 Univ Rutgers Opløste topoisomerase-gifte
AU2003265406A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents

Also Published As

Publication number Publication date
NZ593849A (en) 2014-02-28
SG173454A1 (en) 2011-09-29
EA201101140A1 (ru) 2012-03-30
PE20120112A1 (es) 2012-02-27
KR20110122141A (ko) 2011-11-09
CN102395368A (zh) 2012-03-28
US20120004235A1 (en) 2012-01-05
WO2010088544A1 (en) 2010-08-05
CL2011001850A1 (es) 2012-08-31
JP2012516849A (ja) 2012-07-26
WO2010088544A8 (en) 2011-07-28
EP2391364A1 (en) 2011-12-07
BRPI1008155A2 (pt) 2016-03-08
IL213919A0 (en) 2011-07-31
CA2749204A1 (en) 2010-08-05
MX2011008069A (es) 2011-09-06
AU2010208042A1 (en) 2011-07-21
TW201038578A (en) 2010-11-01
AR075346A1 (es) 2011-03-23

Similar Documents

Publication Publication Date Title
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1120826T1 (el) Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης
CY1119090T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
CR11099A (es) Uso de compuestos inhibidores de quinaxolina de p13k-alfa para el tratamiento del cancer
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112013025969A2 (pt) forma de dose unitária para administração oral
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
NI200900081A (es) Peptidommético smac útiles como inhibidores de iap
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
CL2009000542A1 (es) Uso de un antagonista de c-met y egfr de formula general i para preparar un medicamento para tratar el cancer.
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
MX345780B (es) Inhibidores triciclicos de girasa.
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
ECSP099518A (es) Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico
EA201270728A1 (ru) Пуриновые соединения

Legal Events

Date Code Title Description
FC Application refused